Literature DB >> 24831418

Early switching strategies in antidepressant non-responders: current evidence and future research directions.

Paul A Kudlow1, Roger S McIntyre, Raymond W Lam.   

Abstract

Studies have found that up to two-thirds of patients with major depressive disorder (MDD) do not fully respond to the first antidepressant. While switching antidepressants is a common strategy for antidepressant non-responders, there is still a lack of consensus about the optimal timing of a switch. Many clinicians wait for 6-12 weeks before considering a switch. The objectives of this paper are to (1) review the evidence for positive and negative predictive value (NPV) of early improvement at 2-4 weeks to predict final antidepressant response; (2) review randomized controlled trials (RCTs) that examine early switching strategies; and (3) provide future research directions and clinical recommendations for timing of antidepressant switching. We conducted a literature search for English-language studies via PubMed and Google Scholar, from 1984 to May 2013, with the following terms: 'antidepressants', 'MDD', 'time course', 'trajectory', 'early response', 'onset', 'delayed response', 'early improvement', 'predictors', 'switch', 'combination therapy', and 'augmentation'. Replicated evidence indicates that lack of early improvement (e.g. <20% reduction in a depression scale score) at 2-4 weeks can be an accurate predictor to identify eventual non-responders. The NPVs suggest that only about one in five patients with lack of improvement at 4 weeks will have a response by 8 weeks. Three RCTs examined early switch strategies, but results are inconsistent and comparisons limited by methodological differences. Future studies should incorporate a standard consensus definition of early improvement, discern whether the effect of early switching is specific to certain types of antidepressants, and determine whether early switch is superior to other strategies such as augmentation or combination. Notwithstanding these limitations, there is reasonable evidence to recommend earlier assessment for improvement. If there is no indication of early improvement at 2-4 weeks after starting an antidepressant, and taking into account other patient and clinical factors, a change in management can be considered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831418     DOI: 10.1007/s40263-014-0171-5

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  47 in total

1.  Clinical effectiveness: the importance of psychosocial functioning outcomes.

Authors:  Raymond W Lam; Marie-Josée Filteau; Roumen Milev
Journal:  J Affect Disord       Date:  2011-04-22       Impact factor: 4.839

2.  Early switch strategy in patients with major depressive disorder: a double-blind, randomized study.

Authors:  Irene Romera; Victor Pérez; Jose Manuel Menchón; Alexander Schacht; Rita Papen; Doris Neuhauser; Mocrane Abbar; Pär Svanborg; Inmaculada Gilaberte
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

3.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 4.  Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

Authors:  Henricus G Ruhé; Jochanan Huyser; Jan A Swinkels; Aart H Schene
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

Review 5.  Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement.

Authors:  Paul A Kudlow; Danielle S Cha; Roger S McIntyre
Journal:  Can J Psychiatry       Date:  2012-12       Impact factor: 4.356

6.  Early symptom change prediction of remission in depression treatment.

Authors:  Martin M Katz; Adam L Meyers; Apurva Prakash; Paula J Gaynor; John P Houston
Journal:  Psychopharmacol Bull       Date:  2009

7.  Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

Authors:  Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran
Journal:  J Affect Disord       Date:  2009-08-11       Impact factor: 4.839

8.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

Review 9.  Onset, time course and trajectories of improvement with antidepressants.

Authors:  Raymond W Lam
Journal:  Eur Neuropsychopharmacol       Date:  2012       Impact factor: 4.600

10.  Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis.

Authors:  P Gorwood; F Bayle; G Vaiva; P Courtet; E Corruble; P-M Llorca
Journal:  Eur Psychiatry       Date:  2013-02-14       Impact factor: 5.361

View more
  19 in total

1.  When should governments increase the supply of psychiatric beds?

Authors:  S Allison; T Bastiampillai; J Licinio; D A Fuller; N Bidargaddi; S S Sharfstein
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

Review 2.  Is Empirical Research on Periodization Trustworthy? A Comprehensive Review of Conceptual and Methodological Issues.

Authors:  José Afonso; Pantelis T Nikolaidis; Patrícia Sousa; Isabel Mesquita
Journal:  J Sports Sci Med       Date:  2017-03-01       Impact factor: 2.988

Review 3.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

5.  Estimating outcome probabilities from early symptom changes in cognitive therapy for recurrent depression.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  J Consult Clin Psychol       Date:  2019-04-22

6.  Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings.

Authors:  Arjun P Athreya; Tanja Brückl; Elisabeth B Binder; A John Rush; Joanna Biernacka; Mark A Frye; Drew Neavin; Michelle Skime; Ditlev Monrad; Ravishankar K Iyer; Taryn Mayes; Madhukar Trivedi; Rickey E Carter; Liewei Wang; Richard M Weinshilboum; Paul E Croarkin; William V Bobo
Journal:  Neuropsychopharmacology       Date:  2021-01-15       Impact factor: 7.853

7.  Default mode network deactivation during emotion processing predicts early antidepressant response.

Authors:  M Spies; C Kraus; N Geissberger; B Auer; M Klöbl; M Tik; I-L Stürkat; A Hahn; M Woletz; D M Pfabigan; S Kasper; C Lamm; C Windischberger; R Lanzenberger
Journal:  Transl Psychiatry       Date:  2017-01-24       Impact factor: 6.222

8.  Economic burden of relapse/recurrence in patients with major depressive disorder.

Authors:  Genevieve Gauthier; Lisa Mucha; Sherry Shi; Annie Guerin
Journal:  J Drug Assess       Date:  2019-05-24

9.  Evaluation of the effect of insulin sensitivity-enhancing lifestyle- and dietary-related adjuncts on antidepressant treatment response: protocol for a systematic review and meta-analysis.

Authors:  Olaitan J Jeremiah; Gráinne Cousins; Finbarr P Leacy; Brian P Kirby; Benedict K Ryan
Journal:  Syst Rev       Date:  2019-02-25

10.  Validation of a novel online depression symptom severity rating scale: the R8 Depression.

Authors:  Yuki Takao; Eduardo Figueroa; Kevin Fernand Jean Berna; Youjin Jo; Lee Andrew Kissane; Kimio Yoshimura; Richard Tranter; Richard J Porter
Journal:  Health Qual Life Outcomes       Date:  2021-06-12       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.